From Symptomatic Relief to Tissue Repair
Targeting both the cause and consequence of inflammatory arthritis
A Revolutionary Approach to Rheumatoid Arthritis
Current RA treatments focus primarily on symptom management through immune suppression, leaving joint damage to progress despite reduced inflammation. MEV-N01 represents a fundamentally different approach: a regenerative EV therapy that simultaneously addresses inflammation while actively promoting tissue repair.
Our lead program demonstrates FT-01's therapeutic potential in a large, well-characterised disease with significant unmet medical need. With millions of RA patients worldwide experiencing inadequate response to current treatments, MEV-N01 offers the possibility of not just managing disease but restoring joint function.
Dual-Action Mechanism
Comprehensive Therapeutic Approach
MEV-N01's unique value lies in its ability to target multiple aspects of RA pathology through a single treatment, leveraging the natural therapeutic properties of FT-01-derived EVs.
-
MEV-N01 contains bioactive factors that modulate inflammatory cascades responsible for joint destruction in RA:
Suppression of pro-inflammatory cytokine production
Promotion of anti-inflammatory mediator release
Regulation of immune cell activation and migration
Restoration of immune homeostasis in the joint environment
-
Beyond inflammation control, MEV-N01 actively stimulates repair mechanisms:
Enhancement of chondrocyte function and matrix production
Promotion of synovial tissue healing
Stimulation of endogenous repair pathways
Protection of existing cartilage and bone structures
Clinical Development and Evidence
Validated Efficacy in Disease Models
MEV-N01 has demonstrated compelling therapeutic effects in rigorous preclinical studies using established RA models. These studies validate both the anti-inflammatory and pro-regenerative properties of FT-01-derived EVs.
-
Significant reduction in joint inflammation and swelling
Meaningful improvement in cartilage integrity and bone preservation
Dose-dependent efficacy with weekly and twice-weekly administration
Sustained therapeutic effects following treatment completion
-
No adverse inflammatory responses
Excellent local and systemic tolerability
No evidence of immunogenicity or tumorigenic potential
Compatible with existing RA treatment regimens
Delivery and Patient Benefits
Minimally Invasive Treatment Approach
MEV-N01 is designed for intra-articular injection directly into affected joints, offering several advantages over systemic therapies:
-
Direct application to the disease site maximises therapeutic concentration
Reduced systemic exposure minimises potential side effects
Precise dosing enables optimal therapeutic outcomes
Compatible with outpatient administration
-
Office-based procedure requiring minimal intervention
Potential to delay or prevent joint replacement surgery
Preservation of joint function and mobility
Improved quality of life through pain reduction and functional improvement
Development Timeline and Future Potential
Advancing Toward Clinical Translation
MEV-N01's development pathway reflects our commitment to bringing this innovative therapy to patients while advancing FT-01 platform validation
-
Our development approach aligns with regulatory guidance for advanced therapy medicinal products:
IND-enabling studies planned for completion by late 2026
Clinical trial design informed by preclinical dose-response data
Regulatory engagement to optimise development pathway
Quality systems established for clinical-grade production
-
Expansion into related inflammatory joint conditions
Application to other autoimmune diseases
Platform validation for strategic partnerships
Foundation for next-generation EV therapeutics
Expansion into related inflammatory joint conditions
Application to other autoimmune diseases
Platform validation for strategic partnerships
Foundation for next-generation EV therapeutics